Our Beacon Checkpoint research team and the producers of the 2023 Adenosine-Targeted Cancer Immunotherapies Summit have carefully crafted this free infographic to provide you with a deep dive into the adenosine-pathway clinical trial landscape, using data from the Beacon Checkpoint database.

The data in this infographic reviews:

  • The number of adenosine-pathway targeted therapies entering the clinic since 2011.
  • Status and modalities of adenosine-pathway targeted therapies.
  • Clinical trials by phase over the years.
  • Top disease indications.

To learn more about the adenosine landscape and how Beacon Checkpoint can enhance your data needs and provide fast insights, please book a research session below or contact us directly at beacon@hansonwade.com.

Download the infographic for an up-to-date review of the adenosine-pathway clinical trial landscape.


Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs

Speak with our team

Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated and leveraged on Beacon.

 Get Started